Developing a pipeline around our first in class IL-18 variant, F-18, that can be added to both existing and new therapeutics in a “plug and play” manner. Targeting F-18 offers enhanced efficacy and safety properties capable of overcoming resistance to checkpoint inhibition and other immunotherapies.